Abstract 14909: GLP-1 Receptor Agonist Add-On Therapy versus Continued SGLT2 Inhibitor Monotherapy and Kidney Failure in Adults with Type 2 Diabetes and CKD Stages 3-4: A Propensity-Matched Real-World Analysis
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce kidney and cardiovascular risk in chronic kidney disease (CKD), yet residual risk remains substantial. Whether the addition of glucagon-like peptide-1 receptor agonists (GLP-1RA) provides incremental renal and cardiovascular benefit among patients...